Advanced Practice Professionals Committee

 

Committee Charter

Projects and Objectives

APP Role Description APP Resource Center Committee Members

 

Charter

The Advanced Practice Professionals Committee strives to:

  • Promote and expand the knowledge and professional practice of Advanced Practice Professionals (Advanced Practice Nurses/Nurse Practitioners, Physician Assistants and Pharmacists) engaged in the delivery of cellular therapy to patients.

Projects and Objectives

  • Establish ISCT as the "go to" Society where Advanced Practice Professionals (APPs) can focus on matters related to the optimal delivery of cellular therapy to patients.
  • Develop and implement working APP Subcommittees and Subcommittee Chairs for each of the following groups: (1) Advanced Practice Nurses/Nurse Practitioners, (2) Physician Assistants and (3) Pharmacists.
  • Provide a  global forum for communication, networking and dissemination of knowledge related to cellular therapy for APPs.
  • Promote abstract submissions and poster oral presentations related to the delivery of cell therapy to patients
  • Provide educational programs for APPs at the ISCT annual meetings to update and educate APPs regarding important aspects of cellular therapy through webinars and BEACON Suite of Navigational Tools.
  • Promote the professional roles and clinical practice of APPs within the field of cellular therapy, stem cell transplantation and regenerative medicine.

 

Are you a clinical expert with advanced training?
CLICK HERE to Join ISCT as an APP Member Today

 

Hematopoietic Cell Transplant (HCT) / Immune Effector Cell (ICT)
Advanced Practice Provider (APP) Role Description

Advanced Practice Providers (APPs) include Advanced Practice Nurses (APN) and Physician Assistants (PA) who are licensed health care professionals, integral to the healthcare team. They provide clinical support for patient care by conducting physical exams, prescribing medications, interpreting diagnostic testing, and treating illnesses, in collaboration with a physician. As Physician extenders, APPs can facilitate the delivery of complex patient care involving Hematopoietic stem cell transplant and Immune effector cellular therapies.

HCT/ICT APP CORE COMPETENCIES

  • Maintain competency in the diagnosis and management of patients receiving hematopoietic stem cell transplantation (HCT) and immune effector cell (ICT) therapies.
  • Provide survivorship care to patients, including second malignancy screening, long-term effects of cancer treatment, health promotion.
  • Understand the management of toxicities related to cellular therapy.
  • Complete at least 10 hours of education annually for FACT IEC accreditation.
  • Understand the signs/symptoms of cytokine release syndrome (CRS) and Immune Cell Associated Neurotoxicity Syndrome (ICANS) that can result from cellular therapy.
  • Incorporate evidence-based principles into practice.

HCT/ICT APP CLINICAL ACTIVITIES

  • Promote and provide high-quality patient care as part of a multi-disciplinary team; provide continuity of care.
  • Assist with obtaining proper consent for treatment.
  • Monitor disease response to therapeutic interventions.
  • Recognize, evaluate and treat transplant or cellular therapy complications (including CRS/ICANS toxicities), and rapidly notify the Supervising physician.
  • Communicate clinical status of patient to Physicians, APPs, Pharmacists, Consultants, clinical team.
  • Counsel patients, families, and caregivers about cellular therapy and its potential risks/benefits.
  • Perform advanced patient care diagnostic and therapeutic procedures, including stem cell infusions, administration of cellular therapy products, bone marrow procedures, skin biopsies, lumbar punctures, Ommaya taps and the administration of intrathecal chemotherapy.

HCT/ICT APP PRACTICE-BASED LEARNING

  • Evaluate and identify patients for current clinical trials for transplant and cellular therapy, including comorbidity assessments, and integrate current research into clinical practice.
  • Determine donor selection and eligibility for transplant and cellular therapy.
  • Understand rationale and potential risks/benefits of cellular therapy (including CRS/ICANS).
  • (Reference: ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological ToxicityAssociated with Immune Effector Cells. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2018.12.758)
  • Participate in clinical research opportunities when possible.
  • Train BMT Fellows, APPs, RNs, Residents, Students, and other healthcare team members.
  • Improve clinical workflow, patient safety, quality of care, and access to patient care.


APP Resource Center

 APP Track Presentations Archive

Click here to view APP Track presentations from past ISCT Regional Meetings and Annual Meetings 

 Resource Links for Cellular Therapies

1. CAR T Cells

a. Overview of CAR T 
Chimeric Antigen Receptor T Cells in Hematologic Malignancies. (Pharmacotherapy. 2017 Mar;37(3):334-345. doi: 10.1002/phar.1900. Epub 2017 Feb 22.)

b. CAR T for Acute Leukemia 
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. (Nature Reviews Clinical Oncology. 2019 Jan; 16(1): 45-63. doi: 10.1038/s41571-018-0075-2.)

c. CAR T for Lymphoma 
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. (N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.)

Schuster SJ, Bishop MR, Tam CS, et al. Primary Analysis of Juliet: A Global, Pivotal, Phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2017 [Abstract]; 130: Abstract # 577

d. CAR T Toxicity Grading and Management 
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. (Nature Reviews Clinical Oncology. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.)

Current concepts in the diagnosis and management of cytokine release syndrome. (Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.)

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells. (Biology of Blood and Marrow Transplantation. 2019 Apr; 25(4): 625-638. doi:https://doi.org/10.1016/j.bbmt.2018.12.758.) 

 


 

Committee Chair:


Tobi D. Fisher, MPAS, PA-C
Chair
UT MD Anderson Cancer Center
Houston, TX, United States

 

Committee Members:

 
Kristen B. Kindsvogel, ARNP
Chair, Advanced Practice Registered Nurses Subcommittee
Fred Hutchinson Cancer Research Center
Seattle, WA, United States
Nick Szewczyk, RN, MSN, NP-C
Vice-Chair, Advanced Practice Registered
Nurses Subcommittee
MD Anderson Cancer Center
Houston, TX, United States

Megan Cornelison, MS, PA-C
Vice-Chair, Physician Assistants Subcommittee
MD Anderson Cancer Center
Houston, TX, United States

Mary Alma Welch, PA-C
Vice-Chair, Physician Assistants Subcommittee
MD Anderson Cancer Center
Houston, TX, United States


Valkal Bhatt, PharmD, BCOP, BCPS
Chair, Pharmacists Subcommittee
Memorial Sloan Kettering Cancer Center
New York, NY, United States

 

Alison Gulbis, PharmD
MD Anderson Cancer Center
Houston, TX, United States

 

Are you an APP interested in joining this Committee? Please contact Tobi Fisher and ISCT Head Office with a brief letter of intent and your CV.

© 2019 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy